Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma

References

• Attal M, Harousseau J L, Stoppa A M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Child J A, Morgan G J, Davies F E, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883
   PubMed Web of Science ®Google Scholar
• Abdelkefi A, Ladeb S, Torjman L, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. 2008; 111: 1805–1810
   Google Scholar
• Alvares C L, Davies F E, Horton C, et al. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006; 91: 141–142
   PubMed Web of Science ®Google Scholar
• Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434–2441
   PubMed Web of Science ®Google Scholar
• Fermand J P, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131–3136
   PubMed Web of Science ®Google Scholar
• Lee C K, Barlogie B, Zangari M, et al. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant 2002; 30: 873–878
   PubMed Web of Science ®Google Scholar
• Mehta J, Singhal S. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant 2007; 40: 1101–1114
   PubMed Web of Science ®Google Scholar
• Mehta J, Tricot G, Jagannath S, et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft. Bone Marrow Transplant 1998; 21: 887–892
   PubMed Web of Science ®Google Scholar
• Mehta J, Tricot G, Jagannath S, et al. High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant. Bone Marrow Transplant 1997; 20: 113–116
   PubMed Web of Science ®Google Scholar
• Mikhael J R, Zadeh S, Samiee S, et al. Second autologous stem cell transplant (ASCT) as salvage therapy in patients with relapsed multiple myeloma: improved outcomes in patients with longer disease free interval after first ASCT. ASH Annu Meet Abstr 2007; 110: 946
   Google Scholar
• Morris C, Iacobelli S, Brand R, et al. Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol 2004; 22: 1674–1681
   PubMed Web of Science ®Google Scholar
• Olin R L, Vogl D T, Porter D L, et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009; 43: 417–422
   PubMed Web of Science ®Google Scholar
• Qazilbash M H, Saliba R, De Lima M, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006; 106: 1084–1089
   PubMed Web of Science ®Google Scholar
• Simpson L, Verma R, Kumar S, et al. Outcome after second stem cell transplantation for relapsed multiple myeloma. J Clin Oncol (Meeting Abstracts) 2007; 25: 8118
   Google Scholar
• Sirohi B, Powles R, Rudin C, et al. Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft. Hematology 2005; 10: 361–364
   PubMed Web of Science ®Google Scholar
• Tricot G, Jagannath S, Vesole D H, et al. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995; 16: 7–11
   PubMed Web of Science ®Google Scholar
• Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0. http://ctepcancergov. 2003
   Google Scholar
• Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123
   PubMed Web of Science ®Google Scholar
• Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–494
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123–2132
   PubMed Web of Science ®Google Scholar
• Richardson P G, Sonneveld P, Schuster M W, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
   PubMed Web of Science ®Google Scholar
• Kumar S, Gertz M A, Dispenzieri A, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003; 78: 34–39
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Biagi J J, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102: 69–77
   PubMed Web of Science ®Google Scholar
• Richardson P G, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557–3560
   PubMed Web of Science ®Google Scholar
• Weber D M, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133–2142
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar S V, Dimopoulos M A, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414–423
   PubMed Web of Science ®Google Scholar